BST2 has been shown to activate EGFR and the initiation of downstream signaling pathways by regulating its association with lipid rafts in hepatocellular carcinoma and to be involved in resistance to tumor cell death and chemotherapy (Zhang et al., 2019b). Here, BST2 is linked to hepatocellular carcinoma.